In a $1.05 billion transaction, Merck & Co Inc. has announced this week that it will be buying Peloton Therapeutics. The drug maker will be gaining access to Peloton’s lead kidney cancer drug candidate with the transaction. Peloton expects to start studying its lead drug “PT2977”, a kidney cancer treatment, in a late-stage trial in … Continue reading “Merck & Co Inc. Agrees to Buy Peloton Therapeutics”
